Featured innovator

Data Gumbo CEO discusses Houston's startup ecosystem and goals for his company

Andrew Bruce had the idea for Data Gumbo when he realized how difficult it was to share data in upstream oil and gas. Courtesy of Data Gumbo

For Andrew Bruce, an oil and gas professional and entrepreneur, there's nothing like Houston.

"I've lived in Boston, New York, and London, and I've spent a lot of time in Norway," Bruce says. "They are all wonderful places, but I've never experienced anything quite like Houston."

After a long career in oil and gas, Bruce found himself a victim of the oil downturn. Once laid off, he decided to focus on a new idea for a way to provide access to upstream oil and gas data to companies. He founded Data Gumbo Corp., a blockchain-as-a-service company based in Houston, in 2016. The company closed its seed round last year and is moving toward a series A.

While Bruce credits his trajectory from laid off to startup CEO to a lot of hard work and a bit of blind luck, he says that Houston's people and the help they are willing to provide has been extremely beneficial to the growth of Data Gumbo.

"I'm just brainstorming, but I think a lot of [what makes Houston great for startups] comes from the fact that we all recognize the cyclical nature of the oil and gas industry, we are obligated to look out for each other even when people are laid off," Bruce says. "Maybe it comes from that kind of recognition that we're all in this together and we have to try to work through it."

InnovationMap: Tell me a little bit about your background.

Andrew Bruce: Started out as a programmer, and was transferred from New York City to Houston to build a consulting practice for financial systems. My background originally in London was building systems for the deregulation of banking industry that was happening in the mid 80s.

When I came to houston, I got involved in energy trading systems. I built a small software startup, and eventually got involved in National Oilwell Varco and the drilling business. As part of that, I kicked off a program called NOVOS to build an autonomous drilling rig. Came across the challenge of not having access to data for that rig. Data Gumbo was a direct result of that.

I started Data Gumbo to solve the problem of not being able to get data from industrial installations. Along the way, I came across the opportunity for blockchain because the real problem people were trying to solve was mistrust and inefficiency of the process. I stumbled into blockchain kind of backwards.

IM: How does Data Gumbo work?

AB: The whole idea is to build out the blockchain network, and provide a network that they can subscribe to and start doing business on that network. It's a service, so there's a subscription fee. It gives them access to the savings they already have available within their organizations.

IM: Who are the type of customers you're looking for?

AB: Midstream and upstream oil and gas companies, and the service companies that serve them.

IM: What was the reception like at first?

AB: Difficult. We got a lot of questions and concerns about what blockchain is, why they need it, and whether or not they can trust it. We were introducing a completely new concept to a conservative industry.

IM: What were some challenges and opportunities?

AB: No. 1 is the Operators Blockchain Consortium, which was 19 different oil companies coming together to understand blockchain and its opportunities. That's helped. And 75 percent of our early calls were sort of evangelism of explaining blockchain and how it's different from cryptocurrency. So, it was an educational process. The industry was independently going down the road of understanding the technology. And, to be perfectly honest, it was a bit of blind luck that we chose this technology that the industry was getting behind anyways.

IM: What doors does your recently closed seed round open?

AB: Now we're pursuing a series A equity round. Seed was a bridge to equity funding. It was primarily individuals in town who got behind the company and believed in what we were trying to do. They helped open some doors, but primarily it was financing to get us to series A and prove the concepts from a sales and product market fit perspective.

IM: What are you long-term goals for Data Gumbo?

AB: To take the company public and to remain independent. We believe that we want to provide a service to the customers that is independent from any other offers. We want to stay true to our roots and be a blockchain network infrastructure people can trust and rely on for not just upstream oil and gas, but also getting into trucking and shipping and other adjacent industries so we can satisfy the whole supply chain.

IM: How is it being located in Houston?

AB: Houston's startup community has been amazing. When we started this journey, it had been a while since we had any entrepreneurial contacts, so it was basically like starting from scratch. Organizations like Station Houston and, later on, The Cannon helped provided great contacts. People from those organizations — and the business community as a whole — has been really generous with their time. Houston is probably second to none when it comes to people's willingness to help.

IM: What does Houston still need to work on as an innovation ecosystem?

AB: I don't think it's Houston specifically, but a generalization is that large corporations are set up to buy from large corporations. As a small company or startup to sell to a super major is difficult because the sales cycle is so long and the requirements are set up to buy from other large companies. If there was a way for creating an entrepreneurial division of these companies so that they can experiment with and support startups, that would be tremendous. If you're a startup, you should be focused on sales, but cracking that nut within a large company is really hard.

IM: What keeps you up at night as it pertains to business?

AB: People. I've viewed my roles with a huge responsibility. There are people who make a bet on a company, whether they be investors or employees, and you've got to be able to fund the company. So, whether it be through sales revenue or fundraising, making payroll and building a company that people can get a return on their investment is a huge responsibility. So, that's what keeps me up at night — making sure that I'm repaying people's faith in what we're doing.

------

Portions of this interview have been edited.

Trending News

Building Houston

 
 

The Texas Medical Center Innovation Factory has named the 16 companies making up the inaugural cohort in the Innovate UK Global Incubator Programme. Photo via tmc.edu

Sixteen digital health and medical device startups founded in the United Kingdom have been selected for a customized accelerator at the Texas Medical Center's Innovation Factory.

In partnership with Innovate UK, TMCi created the Innovate UK Global Incubator Programme, a new accelerator that supports UK businesses as they build their United States go-to-market plan. The program builds the BioBridge relationship between TMC and the UK that was originally established five years ago.

“The TMC UK BioBridge program was launched with the UK Department for Business and Trade in 2018 to serve as a gateway for advancing life sciences and foster innovation and research between our two countries," says Ashley McPhail, chief external affairs and administration officer for TMC, in a news release. "We saw an opportunity to work with Innovate UK to develop a larger program with the UK after the success of the 11 companies that previously participated in our health tech accelerator."

The 16 companies will participate in the program from June to November. The cohort is expected to arrive in Houston on June 5 and have access to TMCi's facilities, network of mentors and potential clients, funding, potential customers, and curated programing — all while being a unique entry point into the US. The new offering joins three other globally recognized curriculums: Biodesign, Accelerator for Cancer Therapeutics, and Health Tech.

“TMCi nurtures long-term growth, development, and competitiveness to increase startups chances of success and global expansion," says Emily Reiser, associate director of TMC Innovation. "By bringing their novel technologies and exposing them to a curated selection of TMC’s expert network, startups receive support and evaluation to build, scale, and expand in the US market."

Two of the cohort's specialties include cardiovascular and oncology — two of TMC's strongest areas of expertise — with solutions ranging from surgical devices to AI-enabled risk stratification and hospital efficiency.

Innovate UK is the country's national innovation agency dedicated to supporting business-led innovation in all sectors.

“The United Kingdom is fully committed to improving global healthcare through scientific collaboration," says His Majesty’s Consul General in Texas Richard Hyde in the release. "Through the expansion of the TMC UK BioBridge and in partnership with Innovate UK, this programme will help to expose the brightest and best British companies to the world’s largest medical city. Our companies will collaborate and grow as they work to develop cutting edge technology. The partnership between the UK Government and TMC demonstrates that international collaboration can drive both economic growth and improvement to quality of life.”

The 16 companies making up the inaugural cohort are as follows, according to TMC.

  • AINOSTICS aims to revolutionize the treatment and prevention of neurological conditions, such as dementia, by developing innovative AI-enabled solutions that draw novel insights from routinely acquired non-invasive medical scans to deliver accurate diagnosis and outcome prediction, and in turn facilitate personalized care and timely access to disease-modifying treatments for patients.
  • Alvie is a blended human plus AI-enabled digital solution providing personalised pre and rehabilitation coaching and supportive care for cancer and surgery. Alvie's technology combines data profiling, risk-stratification and tailored prescriptions of health and well-being with curated educational content, targeted behaviour change coaching and expert support through chat messaging and virtual consultations.
  • C the Signs™ is a validated AI cancer prediction platform, which can identify patients at risk of cancer at the earliest and most curable stage of the disease. Used by healthcare professionals, C the Signs can identify which tumor type a patient is at risk of and recommend the most appropriate next step in less than 30 seconds. The platform has detected over 10,000 patients with cancer, with over 50 different types of cancer diagnosed, and with a sensitivity of >98% for cancer.
  • At PEP Health, We believe all patients deserve the best care possible. Our cutting-edge machine-learning technology enables healthcare organisations, regulators, and insurers the real-time, actionable insights they need to have a direct and dramatic impact on patient experiences.
  • PreciousMD improves the lives of lung-cancer and other lung-related illnesses patients worldwide by enabling imaging-based diagnostics needed for personalized treatment pathways.
  • Ufonia is an autonomous telemedicine company, we use large language models and voice AI to increase the capacity of clinical professionals.
  • My mhealth offers digital therapeutics for a range of long-term conditions- COPD, Asthma, Diabetes and Heart Disease. Our product has been successfully deployed in the UK and India, with >100,000 users registered to date. Our solutions empower patients to self-manage their conditions, resulting in dramatic improvements in outcomes, as evidenced through multiple clinical trials and real-world evaluations.
  • At Surgery Hero, we offer a clinically backed solution that ensures whole-human support before and after surgery. We help health systems, employers and health plans cut costs without sacrificing quality of care.
  • Panakeia's software platform enables extremely rapid multi-omics profiling in minutes directly from routinely used tissue images without needing wet lab assays.
  • QV Bioelectronics are striving to deliver longer, better quality lives for brain tumour patients. Using their first-of-its-kind implantable electric field therapy device, GRACE, QV will provide effective, focal & continuous treatment without impacting patient quality of life.
  • 52 North is a med-tech company focused on improving health outcomes and health equity by reinventing care pathways. The NeutroCheck® solution is a finger-prick blood test and digital platform built to significantly improve safety and quality of life for cancer patients, by helping to identify at-home those patients who are at risk of the most fatal side-effect of chemotherapy: neutropenic sepsis.
  • Somnus is fulfilling an unmet need in global healthcare by developing real-time, point of care blood propofol monitoring. Its products will improve the care of sedated and anaesthetised patients, save money for hospitals, and facilitate a major reduction in greenhouse gas emissions.
  • ScubaTx is a breakthrough organ transplant preservation company established to solve the global unmet need for cost-efficient and longer-duration organ preservation technology. ScubaTx has developed a simple, small and affordable device which uses Persufflation to extend the preservation of organs.
  • IBEX is on a mission to help people live active, healthy and productive lives by increasing their access to early diagnosis of osteoporosis. The IBEX BH software as medical device delvers routine, automated assessment of fracture risk from routine radiology for earlier detection and more equitable treatment of osteoporosis.
  • NuVision produces products derived from donated human amniotic membrane that are used in ophthalmology to help patients with chronic, traumatic and post-surgical wounds of the eye to be treated earlier and recover more fully and more quickly. The company’s products are also used in the management of dry eye disease, a debilitating conditions that affects around 17m people in the USA.
  • Calon Cardio-Technology is on a mission to improve quality of life for patients with Left Ventricular Assist devices (LVAD) and reduce the common post operative complications associated with these implantable heart pumps. We plan to do this by introducing a completely wireless heart pump system and augment patient follow-up with built-in remote monitoring capabilities.

Trending News